Sam Brusco, Associate Editor10.05.23
Medtronic presented multi-continent, real-world data that it says demonstrates using MiniMed 780G automated insulin pump with Guardian 4 continuous glucose monitoring (CGM) helps diabetes patients meet or exceed internationally recommended targets, regardless of the region of the world they reside in. The data was presented today at the European Association for the Study of Diabetes (EASD) annual meeting in Hamburg, Germany.
The company’s analysis of data from over 67,000 MiniMed 780G users in Europe, Middle East, Latin America, Oceania, and Asia showed that average glycemic control surpassed targets (ADA guidelines recommend 70% time in range between 70-180 mg/dL). The analysis also made the company determine using recommended MiniMed 780G settings further improves blood sugar outcomes and narrows the difference across regions.
MiniMed 780G’s recently introduced time in tight range (TITR), Medtronic says prior to the success of the system’s initial algorithms was considered an aggressive target for diabetes management, lowers the threshold for TIR to 70-140 mg/dl. MiniMed780G was recently granted Medicare coverage, as well.
Medtronic cited a separate analysis of real-world data for people in the Gulf region, many of whom fast during the month of Ramadan. Fasting carries high risk of complications for type 1 diabetes patients, ranging from hypoglycemia, hyperglycemia, dehydration, and diabetic ketoacidosis, particularly during the fasting hours (from Fajr to Maghrib prayer).
The evidence reportedly highlights how using the MiniMed 780G hybrid, closed-loop system can perform consistently across cultures and adapt to scenarios involving lifestyle changes for people living with type 1 diabetes.
“As AID systems have taken a foothold among western countries, we’ve seen the growing success of outcomes from algorithms, such as SmartGuard technology, to reduce the burden of living with diabetes. That said, there continues to be gaps in access among under-served populations given false perceptions about the impacts of cultural differences to the ultimate success of patients. With the growing body of data, we’re proving that the ideal user of the MiniMed 780G system is anyone who is living with diabetes, regardless of region, religion, or cultural differences,” Federico Gavioli, senior VP of Medtronic Diabetes, EMEA & Americas, told the press.
The company’s analysis of data from over 67,000 MiniMed 780G users in Europe, Middle East, Latin America, Oceania, and Asia showed that average glycemic control surpassed targets (ADA guidelines recommend 70% time in range between 70-180 mg/dL). The analysis also made the company determine using recommended MiniMed 780G settings further improves blood sugar outcomes and narrows the difference across regions.
MiniMed 780G’s recently introduced time in tight range (TITR), Medtronic says prior to the success of the system’s initial algorithms was considered an aggressive target for diabetes management, lowers the threshold for TIR to 70-140 mg/dl. MiniMed780G was recently granted Medicare coverage, as well.
Medtronic cited a separate analysis of real-world data for people in the Gulf region, many of whom fast during the month of Ramadan. Fasting carries high risk of complications for type 1 diabetes patients, ranging from hypoglycemia, hyperglycemia, dehydration, and diabetic ketoacidosis, particularly during the fasting hours (from Fajr to Maghrib prayer).
The evidence reportedly highlights how using the MiniMed 780G hybrid, closed-loop system can perform consistently across cultures and adapt to scenarios involving lifestyle changes for people living with type 1 diabetes.
“As AID systems have taken a foothold among western countries, we’ve seen the growing success of outcomes from algorithms, such as SmartGuard technology, to reduce the burden of living with diabetes. That said, there continues to be gaps in access among under-served populations given false perceptions about the impacts of cultural differences to the ultimate success of patients. With the growing body of data, we’re proving that the ideal user of the MiniMed 780G system is anyone who is living with diabetes, regardless of region, religion, or cultural differences,” Federico Gavioli, senior VP of Medtronic Diabetes, EMEA & Americas, told the press.